Great news, Megagane and thanks.
While not wanting to put a dampener on celebrations, I would question the following…
Importantly this now allows the FDA to priority review Neuron's drug for Rett syndrome which is very bullish for receiving breakthrough designation. Orphan drug designation bodes very well for the next step in breakthrough designation…
Priority review is something that can only applied for around the time of submitting application for marketing approval, so it doesn’t come into play at this point. Having orphan drug designation, btw, doesn’t automatically entitle its sponsor to priority review.
Also, I don’t think that receiving orphan drug designation should be construed as a bullish sign that the drug will also be granted breakthrough therapy designation. These two designations are unrelated, imo. It should be remembered that efficacy hurdles are much higher for BTD than with orphan drug designation. Orphan drug designation only requires that a medically plausible rationale be presented which suggests that the drug might have a favourable effect on the disease. One third of orphan drugs are designated on the basis of in vitro or animal data only. BTD, on the other hand, requires some sound clinical data evidence of substantial impact on one or more clinically meaningful endpoints.
- Forums
- ASX - By Stock
- NEU
- FDA Grants Orphan Drug Designation
FDA Grants Orphan Drug Designation, page-11
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.18 |
Change
-0.430(3.16%) |
Mkt cap ! $1.684B |
Open | High | Low | Value | Volume |
$13.64 | $13.67 | $13.18 | $8.868M | 666.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 5233 | $13.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.24 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 5233 | 13.180 |
1 | 2135 | 13.170 |
2 | 1561 | 13.160 |
1 | 2135 | 13.150 |
3 | 2356 | 13.130 |
Price($) | Vol. | No. |
---|---|---|
13.240 | 1000 | 1 |
13.290 | 3819 | 3 |
13.300 | 2000 | 1 |
13.310 | 2135 | 1 |
13.340 | 2135 | 1 |
Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online